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StatisticalTestsUsedtoValidate theAmericanJoint
CommitteeonCancerEighthEditionPrognosticStage
ComparedWith theAnatomicStage inBreastCancer
To the EditorWeiss et al1 validated theAmerican Joint Commit-
tee on Cancer Eighth Edition prognostic stage and compared it
with the anatomic stage in breast cancer in 2 large cohorts. The
authors used theHarrell C index to qualify themodels’ predic-
tiveperformancebasedonprognostic stageandanatomicstage,
respectively.Theauthorsfurtherdeterminedthesignificancebe-
tween theHarrell C indexof the prognostic stage and anatomic
stage using the R package compareC. In the MD Anderson co-
hort, theHarrell C indices for the prognostic stage and the ana-
tomic stage are 0.8357 and 0.7370 (P < .001). In the California
CancerRegistry, theHarrellC indicesfortheprognosticstageand
the anatomic stage are 0.8426 and 0.8097 (P < .001).
With censored data, it is well known that the Harrell C
index can overestimate the C index.Weiss et al1 did not report
theproportionof censoreddata for the 2 cohorts. Basedon the
Kaplan-Meier curves in the article, the 2 cohorts have approxi-
mately75%subjects forwhomnoeventwasobservedandwho
werecensoredattheendofthestudy,especiallythosewithstage
IA to IIBdisease.Furthermore, toprovideavalid inference, the
method implemented in the R package compareC requires a
strong condition thatmight not hold in practice.2 If the condi-
tiondoesnot hold, the compareCmethod can induce a serious
bias and inflated type I error.2 An alternative way is to use the
inverse probability of censoringweighting estimator proposed
by Uno et al3 (R package SurvC1), but the biasmay be nonneg-
ligible if the censoredproportion ishigh.2Anotherway is to as-
sume a Cox proportional hazards (PH) model or proportional
odds model and then apply the method proposed by Gonen
and Heller4 (R package CPE) or Zhang and Shao5 (R package
evacure) to estimate and compare the concordance indices.
TheauthorsalsoreporttheAkaikeinformationcriterion(AIC)
to compare model fits. For univariate analysis, the Harrell C
index and the inverse probability of censoringweighted C sta-
tistics canbeestimateddirectlywithoutassumingamodel. It is
notclearwhyamodel is requiredtoestimatetheCindexandfur-
thercompare themodelbyusing theAIC.TheGonenandHeller
estimator requires aCoxPHmodel, yet thegoodness-of-fit test
of theCoxPHmodel ismore important thantheAICbecausethe
violation of the PH assumption can lead to a biased estimator.
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Estimating and Interpreting theOverall Survival
Benefit of Checkpoint Inhibitors viaMeta-analysis
To the EditorLee et al1 conducted an interestingmeta-analysis
to estimate the relative efficacy of checkpoint inhibitor vs do-
cetaxel for treatment of advanced non–small cell lung carci-
noma. The meta-analysis consists of 5 comparative clinical
trials (CheckMate-017, CheckMate-057, Keynote-010, OAK,
POPLAR) with the overall survival (OS) end point. For each
study, the hazard ratio (HR) was used to quantify the treat-
ment effect. A weighted average of 5 HRs was constructed as
the pooled treatment effect from checkpoint inhibitors using
the fixed-effects inverse-variance-weightedmethod. This re-
sulted in a combined HR (checkpoint inhibitor vs docetaxel)
of 0.69 (95% CI, 0.63-0.75).
There are a couple of issues regarding thismeta-analysis.
First, except forCheckMate-017, checkpoint inhibitorshadde-
layed clinical OS benefit. That is, Kaplan-Meier curves for 2
treatment groups in each trial overlapped considerably for the
early part of the study. Thus, the HR was not a constant over
the entire study follow-up time. For this situation, itwould be
difficult to interpret individual HRs clinically and the HR es-
timate would not be an appropriate measure to quantify the
OSbenefit fromcheckpoint inhibitoruse.2,3 Second,evenwhen
the HRwas constant over time for each study, one would not
be able to identify ameaningful patient population for which
the aforementioned pooled estimate of 0.69 could be inter-
preted as its HR unless those 5 underlying HRs are identical
(an unlikely scenario).4
For a single study, a robust alternative summary for thebe-
tween-treatment difference in OS could be the difference of 2
survival ratesor restrictedmeansurvival times (RMST)ataspe-
cific timepoint.2,3 For example, forCheckMate-057,RMSTs for
OS with 24-month follow-up were 13.0 and 11.3 months for
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